tiprankstipranks
Luye Pharma Group Ltd. (LYPHF)
OTHER OTC:LYPHF
US Market
LYPHF
Luye Pharma Group
RESEARCH TOOLSreports
Want to see LYPHF full AI Analyst Report?

Luye Pharma Group (LYPHF) Stock News & Sentiment

3 Followers
Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015
Premium
Company Announcements
Luye Pharma Starts U.S. PK Bridging Trial for Novel CNS Drug LY03015
15d ago
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
Premium
Company Announcements
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
20d ago
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
Premium
Company Announcements
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
27d ago
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
Premium
Company Announcements
Luye Pharma Delivers Double-Digit Profit Growth in 2025 but Skips Dividend
1M ago
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
Premium
Company Announcements
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
2M ago
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
Premium
Company Announcements
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
3M ago
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
Premium
Company Announcements
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
3M ago
More LYPHF News >

LYPHF News on the Web

Luye Pharma Group (LYPHF) Receives a Buy from SDIC Securities
TipRanks News
Bullish
Luye Pharma Advances Alzheimer’s Psychosis Drug LY03017 Into China Phase II Trial
TipRanks News
Bullish
Luye Pharma Group (LYPHF) Receives a Buy from Citi
TipRanks News
Bullish
Luye Pharma Starts Phase II Trial in China for Next-Generation Schizophrenia Drug LY03020
TipRanks News
Bullish
Luye Pharma Sets March 2026 Board Meeting to Approve 2025 Results
TipRanks News
Neutral
Luye Pharma Completes RMB1.09 Billion Transfer of 25% Stake in Nanjing Luye to NJ Xinshi
TipRanks News
Neutral
Luye Pharma Injects RMB285 Million into Nanjing Unit via Structured Deal
TipRanks News
Neutral
Luye Pharma’s Ruoxinlin NDA for Anxiety Disorder Accepted in China, Targeting Major CNS Market Gap
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
LYPHF
Sector Average
Media Buzz
This Week3 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is LYPHF’s Media Buzz Sentiment?
3 articles about LYPHF were published this week. In an average week, 1 articles are published.
    What is LYPHF’s weekly average amount of articles?
    In an average week, 1 articles about LYPHF are published.
      What is LYPHF’s News Sentiment?
      100% of articles about LYPHF were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week